Salarius Pharmaceuticals, Inc. (SLRX)

NASDAQ: SLRX · IEX Real-Time Price · USD
0.225
0.00 (0.00%)
Aug 16, 2022 11:27 AM EDT - Market open
0.00%
Market Cap 12.63M
Revenue (ttm) n/a
Net Income (ttm) -18.67M
Shares Out 56.12M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 50,952
Open 0.225
Previous Close 0.225
Day's Range 0.222 - 0.230
52-Week Range 0.160 - 1.200
Beta 1.37
Analysts Buy
Price Target 5.10 (+2,166.7%)
Earnings Date Aug 5, 2022

About SLRX

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect... [Read more...]

Industry Biotechnology
CEO David Arthur
Employees 16
Stock Exchange NASDAQ
Ticker Symbol SLRX
Full Company Profile

Financial Performance

In 2021, SLRX's revenue was $1.84 million, a decrease of -64.84% compared to the previous year's $5.23 million. Losses were -$12.77 million, 73.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for SLRX stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 2,166.67% from the latest price.

Price Target
$5.1
(2,166.67% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Multiple development and data milestones expected from seclidemstat and SP-3164 programs in 2H22 Conference call and webcast today at 11:00 a.m. ET Multiple development and data milestones expected from...

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ong...

Clinical Trial Now Expands to Fifteen U.S. Trial Sites Clinical Trial Now Expands to Fifteen U.S. Trial Sites

Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatmen...

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday,...

Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET

Salarius Pharmaceuticals to Participate in BIO International Convention 2022

HOUSTON, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatme...

Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatr...

Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug A...

Salarius planning for SP-3164 IND Application Submission in 2023 Salarius planning for SP-3164 IND Application Submission in 2023

Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress

Conference Call and Live Audio Webcast Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET

Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering

HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment op...

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results

Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies

Insiders Buying These 4 Penny Stocks

US stock futures traded lower this morning after the Dow Jones gained more than 650 points on Wednesday. Investors, meanwhile, focused on some notable insider trades When insiders purchase or sell share...

Other symbols: AKASKLZVLDR

Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company P...

Conference Call and Live Audio Webcast Scheduled for Thursday, March 10, 2022, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, March 10, 2022, 5:00 p.m. ET

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference

HOUSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Dr. Santiesteban will lead the development of SP-3164 and other targeted protein degradation assets Dr. Santiesteban will lead the development of SP-3164 and other targeted protein degradation assets

Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Port...

Conference call and live audio webcast scheduled for today at 8:30 a.m. EST Conference call and live audio webcast scheduled for today at 8:30 a.m. EST

Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase an...

HOUSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors,...

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Ewing sarcoma arm advances to second lead-in safety dosing cohort in Sarcoma trial evaluating seclidemstat in combination with chemotherapy agents in patients with relapsed/refractory Ewing sarcoma and ...

Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum

HOUSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...

Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference

HOUSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...

Salarius (SLRX) Reports Q3 Loss, Misses Revenue Estimates

Salarius (SLRX) delivered earnings and revenue surprises of 11.11% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Cash and Cash Equivalents of $31.9 Million Sufficient to Fund Completion of Ongoing Clinical Trials for Lead Drug Candidate Seclidemstat

Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know

Salarius (SLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress

Conference Call and Live Audio Webcast Scheduled for Thursday, November 4, 2021, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, November 4, 2021, 5:00 p.m. ET

Salarius Pharmaceuticals and Nationwide Children's Hospital Disclose Research Findings from Presentation at 2021 AACR...

HOUSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...